Physician profile
Ashley Hardeman
NPI 1356932032
$7,610.70
in general payments reported to CMS, 2019-2025
58 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $981 · 2022: $1,539 · 2023: $1,920 · 2024: $1,879 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,066 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,065.51 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.66 | 2021-2025 | |
| Amgen INC. | $988.72 | 2021-2025 | Evenity, Otezla, Prolia |
| Novo Nordisk INC | $825.38 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $587.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.84 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $359.31 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.10 | 2021-2025 | Xifaxan |
| Pfizer INC. | $330.96 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.20 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $201.44 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $171.94 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $140.72 | 2022-2024 | Quviviq |
| Dexcom, INC. | $127.42 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $122.83 | 2022 | |
| Phathom Pharmaceuticals, INC. | $112.97 | 2024-2025 | Voquezna |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hardeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.